4D Molecular Therapeutics, Inc. Earnings Per Share, Basic and Diluted
4D Molecular Therapeutics, Inc. (FDMT) reported Earnings Per Share, Basic and Diluted of -$0.82 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-12
- 4D Molecular Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.82.
- 4D Molecular Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.82.
- 4D Molecular Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.82.
- 4D Molecular Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.28.
- 4D Molecular Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$2.57.
- 4D Molecular Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$8.82.
- 4D Molecular Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$9.59.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.82 10-Q · filed 2022-05-12 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$2.46 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$2.79 derived: net income ÷ weighted average shares · filed 2023-05-11 |
| 2021-12-31 | -$0.82 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.65 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.96 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$2.57 10-K · filed 2022-03-28 |
| 2021-09-30 | -$0.82 10-Q · filed 2021-11-10 | -$1.11 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.72 10-Q · filed 2021-11-10 | -$2.95 derived: net income ÷ weighted average shares · filed 2022-11-08 |
| 2021-06-30 | -$0.28 10-Q · filed 2021-08-12 | -$0.90 10-Q · filed 2021-08-12 | -$2.10 derived: net income ÷ weighted average shares · filed 2022-08-11 | -$3.05 derived: net income ÷ weighted average shares · filed 2022-08-11 |
| 2021-03-31 | -$0.61 10-Q · filed 2022-05-12 | -$2.01 derived: net income ÷ weighted average shares · filed 2022-05-12 | -$3.20 derived: net income ÷ weighted average shares · filed 2022-05-12 | -$5.08 derived: net income ÷ weighted average shares · filed 2022-05-12 |
| 2020-12-31 | -$2.02 derived: net income ÷ weighted average shares · filed 2022-03-28 | -$3.70 derived: net income ÷ weighted average shares · filed 2022-03-28 | -$6.36 derived: net income ÷ weighted average shares · filed 2022-03-28 | -$8.82 10-K · filed 2022-03-28 |
| 2020-09-30 | -$1.51 10-Q · filed 2021-11-10 | -$4.43 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$6.97 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$2.92 10-Q · filed 2021-08-12 | -$5.46 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$2.54 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$9.59 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |